COMMUNIQUÉS West-GlobeNewswire

Cutera to Present at the 2018 UBS Global Healthcare Conference
26/04/2018
BRISBANE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq: CUTR ), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that James Reinstein, [...]
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
26/04/2018
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that research describing the [...]
Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
26/04/2018
CRANBURY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for [...]
Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress
26/04/2018
Average time to second administration was more than 16 weeks 74% of patients received second administration of ZILRETTA between Weeks 16 and 24 Results indicate robust treatment response in a “real-world” patient group [...]
Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance
26/04/2018
CINCINNATI, April 26, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today: GENERAL HIGHLIGHTS Reported record fiscal 2018 second quarter and first six months net revenues of $56.5 million and $108.7 [...]
Strongbridge Biopharma plc to Host First Quarter 2018 Financial Results Conference Call on May 10, 2018
26/04/2018
DUBLIN, Ireland and TREVOSE, Pa., April 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
Jeffrey Davidson joins Karmanos Cancer Institute Board of Directors
26/04/2018
DETROIT, April 26, 2018 (GLOBE NEWSWIRE) -- Jeffrey Davidson has joined the Barbara Ann Karmanos Cancer Institute Board of Directors for a three-year term, effective immediately. Davidson will collaborate with other [...]
Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American Society of Clinical Oncology
26/04/2018
Researchers Will Present New Data from the Ongoing Phase 1b/2 Advanced Ovarian Cancer Study in Collaboration with Incyte HALIFAX, Nova Scotia, April 26, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX: [...]
Shire plc : 1st Quarter Results
26/04/2018
Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018 Growth driven by Immunology, recently-launched products, and international expansion Innovative pipeline progresses with 15 programs in [...]
Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018
26/04/2018
THE WOODLANDS, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), will release its first quarter 2018 financial results on Thursday, May 3, 2018 before market opens. Management will [...]
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
26/04/2018
Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: [...]
Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018
26/04/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, April 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Aino Health AB (publ): Notice of annual general meeting of aino health ab (publ)
26/04/2018
April 26, 2018 Notice of annual general meeting of aino health ab (publ) Shareholders in Aino Health AB (publ), company reg. no. 559063-5073 ("the Company") are hereby notified of the Annual General Meeting which will [...]
Enzymatica AB: Continued growth during the first quarter
26/04/2018
Interim report for Enzymatica AB (publ) JANUARY- MARCH 2018 Continued growth during the first quarter First quarter Net sales reached SEK 15.1 (9.6) million. Net profit after tax came in at SEK -10.1 (-11.4) million. [...]
C-RAD AB – Interim report January-March 2018
26/04/2018
CONTINUED STRONG GROWTH, REVENUE INCREASED BY 31 PERCENT JANUARY - MARCH 2018 Order intake: 50.6 (40.2) MSEK, 26%. Revenues: 33.8 (25.8) MSEK, 31%. Operating profit: -4.7 (-5.7) MSEK. Net results after tax: -4.9 (-5.8) [...]
Shire plc : Rule 2.9 Announcement
26/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 26 April 2018 [...]
Financière de Tubize SA: Approval of dividend
26/04/2018
Press release FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, general manager, aspijcke@icloud.com Approval of dividend Regulated information 25 April 2018 The general [...]
Financière de Tubize SA: Approbation du dividende
26/04/2018
Communiqué de presse FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: aspijcke, directeur, aspijcke@icloud.com Approbation du dividende Information réglementée 25 avril 2018 L'assemblée générale [...]
Saniona progress to second part of Phase 2a study for Tesomet in Prader-Willi Syndrome based on positive results in adult patients
26/04/2018
PRESS RELEASE April 26, 2018 Saniona, a leading biotech company in the field of ion channels, today announced that it has obtained approval to initiate the second part of its Phase 2a trial for Tesomet in adolescents [...]

Pages